EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies

Robert Paris

The Journal of Infectious Diseases · 04.08.2023 · 228 (Supplement_1) · S24-S33

DOI: 10.1093/infdis/jiad145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 04.08.2023. Verfasst von Robert Paris. Beteiligte Einrichtung: Moderna, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ModernaTX Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary immunodeficiencies (PIDs) are heterogeneous, rare disorders that increase susceptibility to infection and/or immune dysregulation. Individuals with certain PIDs are at high risk of severe or fatal outcomes from SARS-CoV-2 infections (the causative agent of COVID-19), either due to the underlying PID and/or due to the presence of comorbidities such as severe lung and liver disease. Vaccination remains the primary strategy to protect individuals with PID from COVID-19. However, populations with PID exhibit variable vaccine seroresponse rates, antibody titers, and neutralization activity depending on the type of PID and/or COVID-19 vaccine, and consequently, are at an elevated risk of severe disease. In this article, we review the COVID-19 burden in patients with PIDs and focus in-depth on findings from patients with predominantly antibody deficiencies or combined immunodeficiencies. We conclude by providing COVID-19 vaccination recommendations for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansCOVID-19 VaccinesSARS-CoV-2VaccinationPatientsAntibodies, Viral

Stichwörter der Autor:innen

COVID-19SARS-CoV-2mRNAprimary immunodeficienciesvaccination

Substanzen

COVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Moderna, Inc., Cambridge, Massachusetts, USA.
  • Department of Medicine, Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Förderung

  • ModernaTX Inc

Zitieren

APA

Paris, R. (2023). SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies. The Journal of Infectious Diseases, 228(Supplement_1), S24-S33. https://doi.org/10.1093/infdis/jiad145

Vancouver

Paris R. SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies. The Journal of Infectious Diseases. 2023;228(Supplement_1):S24-S33. doi:10.1093/infdis/jiad145

BibTeX
@article{Paris2023,
  author = {Paris, Robert},
  title = {SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  volume = {228},
  number = {Supplement_1},
  pages = {S24--S33},
  doi = {10.1093/infdis/jiad145}
}
Kostenlos starten →